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ABSTRACT 
Ayurveda, the science of life helps in the management of diseases through its various branches among 
which Rasashastra is Ayurvedic pharmaceutics, which deals with the drugs of mineral origin, their varieties, 
characteristics, processing techniques, properties and their therapeutic uses. Formulation in the proposed 
study two different Guggulu preparations Kaisore Guggulu and Amrutadi Guggulu has been selected whose 
indications are for Vatarakta apart from other diseases. In the day to day practice the physicians of 
Ayurvedic fraternity of Odisha use these two medicines in the treatment of Vatarakta. Its incident is said to 
be 0.2 - 0.3 among the world population and its curability is still apprehensive in remedial field. 
This is study with comparison by a known standard drugs, carried out on 60 number of patients 
suffering from Vatarakta Will be selected from the OPD/IPD of Gopabandhu Ayurveda Mahavidyalaya and 
Hospital, Puri. An overall clinical implement and statistical assessment are also witnessed in favour of trial 
drugs in a significant manner. Correction in laboratory investigation is also another beneficent favour of 
drug appended. The question of acceptability of the trial drugs for the treatment of Vatarakta is no more 
remains apprehended rather it can be safely used for the purpose. From the observation of my study it is 
found that both the drugs are effective in reducing the sign and symptoms of Vatarakta but while coming to 
the comparison Amrutadi Guggulu is more effective than the Kaisora Guggulu in the present study. 
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INTRODUCTION
 Rasashastra is Ayurvedic pharmaceutics, which 
deals with the drugs of mineral origin, their varieties, 
characteristics, processing techniques, properties and 
their therapeutic uses. 
Thus, ‘Rasashastra’ means the science of conversion 
of the drugs, irrespective of their nature (herbal, mineral, 
animal) into rasa form, which can be easily absorbed and 
assimilated. 
Kasaya Kalpana has been told as the basic kalpana 
of all other kalpanas. Guggulu kalpana is an upgraded form 
of Kalka kalpana in which Guggulu is the main ingredient 
and it is a part of Vati Kalpana [1]. Guggulu kalpas are 
among some of the most familiar preparations in 
Ayurvedic pharmacopea.[2] Among these Guggulu 
preparations Kaisore Guggulu and Amrutadi Guggulu are 
two such preparations which are predominantly used in 
the disease Vatarakta (Gouty arthritis). 
 Keeping an eye to the salient features of an ideal 
formulation in the proposed study two different Guggulu 
preparations Kaisore Guggulu and Amrutadi Guggulu has 
been selected whose indications are for Vatarakta apart 
from other diseases. In the day to day practice the 
physicians of Ayurvedic fraternity of Odisha use these two 
medicines in the treatment of Vatarakta 
Its incident is said to be 0.2 – 0.3 among the world 
population and its curability is still apprehensive in 
remedial field. The similarity of disease goes more in 
favour of gouty arthritis as in grouped in modern classics. 
The disease is not fatal but incapacitating in nature after a 
chronicity of 1 yr. 
As regards treatment a satisfactory cure is still 
limited. To improve various range which is truly the prime 
lookout among medicos working in various fields. 
Disability of various range and handicap – endness are also 
considered to be disturbing ailments met with the disease 
Vatarakta. To overcome this, scientists are still engaged to 
find out a suitable remedy fitting to the condition. In this 
context course of action indicating various remedies have 
been prescribed in Ayurvedic classics. The present 
endeavour is one of them to find out the possibility of 
relief leading to cure up to satisfaction. 
MATERIALS AND METHOD 
This is study with comparison by a known standard 
drugs, carried out on 60 number of patients suffering from 
Vatarakta Will be selected from the OPD/IPD of 
Gopabandhu Ayurveda Mahavidyalaya and Hospital, Puri 
following the selection criteria and were divided into two 
groups randomly viz. 
Group I: 30 patients were treated with trial drug 1 i.e. 
Kaiosore Guggulu. 
Group II: 30 patients were treated with trial drug 2 i.e. 
Amrutadi Guggulu 
Selection Criteria 
 The patients are selected as per the inclusion and 
exclusion criteria described as below.  
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Inclusion Criteria  
The selection is made referring to cardinal signs and 
Symptoms such as. 
1. Swelling of joints  
2. Pain 
3. Tenderness   
4. Burning sensation 
5. Elevated serum uric acid   
6. Elevated E.S.R. 
Exclusion Criteria  
1. Cardio / Renal pathology    
2. Hypertension  
3. Osteoarthritis     
4. Rheumatoid arthritis 
5. Pregnant & lactating mother  
6. Diabetes, Tuberculosis and other systemic diseases 
7. Below 20 years of age. 
Study Design: The total numbers of patients i.e. 60 have 
been selected applying multiphase random sampling 
techniques and were divided into two groups as follows.  
GI = Group I = Consisting 30 patients  
GII =Group II = Consisting 30 patients 
Duration of Study: Total duration of the study is 18 
months. 
Drug and Dose  
Group 1 – Kaisore Guggula was given in 3gms tablet at 6 
A.M. and 6 P.M. at divided doses. 
Group 2 – Amrutadi Guggula was given in 3gms tablet at 6 
A.M. and 6 P.M. at divided doses. 
Clinical assessment of cases 
 The clinical assessment was made depending 
upon the changes in subjective and objectives features as 
mentioned in assessment scale. 
Subjective Criteria  
1. Pain 
G0- Absent or no Pain 
G1- Mild- Perception of pain but not interfering his 
normal activities. 
G2- Moderate- Perception of pain, interfering his 
normal activities and painful activities. 
G3- Severe- Excruciating of pain associated with painful 
crises and agonizing look. 
2. Swelling 
 The affected joint and particular normal joint of 
the patient was measured. The difference between the two 
was taken. When there was incidence of both side joint 
afflictions then a normal person of same height and weight 
was considered. The difference between the 
measurements of the particular joint of the affected person 
with that of the normal individual was taken and grouped 
as mild, moderate and severe.   
3. Burning sensation 
G0- Normal 
G1- Mild- Feeling of burning sensation  
G2- Moderate- Feeling of burning sensation on 
extremities as well as on forehead 
G3- Severe- Feeling of burning sensation all over the 
body  
Objective Criteria 
1. Blood serum Uric Acid Level 
G0- Normal- 5- 7 mm of fall/ 1st hour 
G1- Mild- 7- 20 mm of fall/ 1st hour 
G2- Moderate- 20- 50 mm of fall/ 1st hour 
G3- Severe- > 50 mm of fall/ 1st hour 
2. Blood ESR 
G0- Normal- 5- 7 mg/dl 
G1- Mild- 7- 8 mg/dl 
G2- Moderate- 8- 9 mg/dl 
G3- Severe- > 9 mg/dl  
Assessment Scale: The effectiveness of trail and control 
drug has been assessed through the p – value applying 
paired T – test for test of significance.  
Result 
After the study the fallowing results are observed in 
the study. The percentage of change with w.r.t sign 
symptoms after 15, 30 and 45 days of treatment inGroup-1 
and Group-II. 
Sign and symptoms Group-I Group-II 
AT1 
P* 
AT2 
P* 
AT3 
P* 
AT1 
P* 
AT2 
P* 
AT3 
P* 
Pain 20.96 30.64 48.38 27.11 42.37 67.79 
Swelling 24.24 50 60.6 32.2 60.4 74.57 
Burning Sensation 10.5 15.54 22.91 13.42 27.33 39.02 
ESR 1.07 2.61 5.69 1.18 2.37 4.13 
Uric Acid 10.95 1.95 31.47 14.8 29.93 37.25 
P* = Percentage of patient improved, AT1 = After 15 days of treatment, AT2 = After 30 days of 
treatment, AT3 = After 45 days of treatment  
Clinical Assessment 
Clinical Assessment 
 
 AT1  AT2  AT3 
Gr I Gr II Gr I Gr II Gr I Gr II 
N PI (%) N PI (%) N PI (%) N PI (%) N PI (%) N PI (%) 
Well responded (>75%) - - - - - - - - 2 13.33 3 20 
Moderately responded (>50%) 2 13.33 3 20 4 26.67 6 40 5 33.33 7 46.67 
Poorly responded (> 25%) 3 20 6 40 6 40 5 33.33 5 33.33 3 20 
Not Responded (< 25%) 10 66.67 6 40 5 33.33 4 26.67 3 20 2 13.33 
N- Number of Patient, PI- Percentage of Improvement 
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The above table shows that among the 15 cases of Group-I fallowing results were found. After 15 days of treatment 
2 (13.33%) moderately responded, 3 (20%) poorly responded and 10 (66.67%) did not responded. After 30 days of 
treatment 4 (26.67%) moderately responded, 6 (40%) poorly responded and 5 (33.33%) did not responded. After 45 days 
of treatment 2 (13.33%) patients are well responded, 5 (33.33%) moderately responded, 5 (33.33%) poorly responded 
and 3 (20%) did not responded. 
The above table shows that among the 15 cases of Group-II fallowing results were found. After 15 days of treatment 
3 (20%) moderately responded, 6 (40%) poorly responded and 6 (40%) did not responded. After 30 days of treatment 6 
(40%) moderately responded, 5 (33.33%) poorly responded and 4 (26.67%) did not responded. After 45 days of 
treatment 3 (20%) patients are well responded, 7 (46.66%) moderately responded, 3 (20%) poorly responded and 2 
(13.33%) did not responded. 
Table Showing Statistical Analysis of various subjective and objective parameters of Vatarakta 
Parameters Groups Mean ± S.D D.F t value P value Remarks 
1. Pain Gr-I 4.13±1.59 (BT) 
3.26±1.83 (AT1) 
2.8±1.69 (AT2) 
2.13±1.72 (AT3) 
14  
5.28 
7.74 
10.32 
<0.001 
<0.001 
<0.001 
*** 
*** 
*** 
Gr-II 3.93±1.33 (BT) 
2.86±1.59 (AT1) 
2.13±1.45 (AT2) 
1.26±1.38 (AT3) 
14  
6.95 
7.21 
12.70 
<0.001 
<0.001 
<0.001 
*** 
*** 
*** 
2. Swelling Gr-I 4.4±2.33 (BT) 
4.00±3.13 (AT1) 
2.2±2.7 (AT2) 
1.73±2.78 (AT3) 
14  
3.39 
4.11 
4.82 
<0.01 
<0.01 
<0.001 
*** 
*** 
*** 
Gr-II 3.33±2.15 (BT) 
2.66±1.63 (AT1) 
1.4±1.35 (AT2) 
1.00±1.06 (AT3) 
14  
4.02 
4.06 
4.97 
<0.01 
<0.01 
<0.001 
** 
** 
*** 
3.Burning 
Sensation 
Gr-I 42.46±7.08 (BT) 
38.4±6.03 (AT1) 
35.86±5.83 (AT2) 
32.6±5.14 (AT3) 
14  
6.12 
7.69 
7.87 
<0.001 
<0.001 
<0.001 
*** 
*** 
*** 
Gr-II 42.2±7.86 (BT) 
36.53±10.9 (AT1) 
30.66±3.28 (AT2) 
26.73±3.26 (AT3) 
14  
9.48 
13.48 
14.28 
<0.001 
<0.001 
<0.001 
*** 
*** 
*** 
4.Uric Acid Gr-I 41.07±18.70 (BT) 
36.86±17.65 (AT1) 
32.13±18.95 (AT2) 
29.00±19.67 (AT3) 
14  
5.80 
5.78 
6.79 
<0.001 
<0.001 
<0.001 
*** 
*** 
*** 
Gr-II 43.66±15.54 (BT) 
37.33±16.97 (AT1) 
31.46±18.06 (AT2) 
27.04±17.55 (AT3) 
14  
6.01 
7.90 
9.30 
<0.001 
<0.001 
<0.001 
*** 
*** 
*** 
5. ESR Gr-I 8.66±0.52 (BT) 
8.57±0.53 (AT1) 
13.12±17.95 (AT2) 
13.14±19.61 (AT3) 
14  
4.35 
4.73 
6.32 
<0.001 
<0.001 
<0.001 
*** 
*** 
*** 
Gr-II 14.02±20.19 (BT) 
8.63±0.58 (AT1) 
8.46±0.63 (AT2) 
8.2±0.71 (AT3) 
14  
6.19 
9.12 
8.97 
<0.05 
<0.05 
<0.05 
# 
# 
# 
# Insignificant at 5% level (> 0.05), * Significant at 5% level (<0.05), ** Significant at 1% level (<0.01), *** 
Significant at 0.1% level (<0.001) 
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The statistical analysis shows that in case of pain in 
Vatarakta in Group-I, the mean ± S.D before treatment was 
4.13 ± 1.59 and reduced to 3.26 ± 1.83 after 15 days, 2.8 ± 
1.69 after 30days and 2.13 ± 1.72 after 45 days of 
treatment. 
 In Group-II, the mean ± S.D before treatment was 
3.93 ± 1.33 and reduced to 2.866 ± 1.59 after 15 days, 2.86 
± 1.59 after 30days and 1.26 ± 1.38 after 45 days of 
treatment. The test of significance shows that both Group-I 
and Group-II are highly significant with p- Value <0.001. 
 In case of swelling in Vatarakta in Group-I, the 
mean ± S.D before treatment was 4.4 ± 2.33 and reduced to 
4.00 ± 3.13 after 15 days, 2.2 ± 2.7 after 30days and 1.73 ± 
2.78 after 45 days of treatment. 
 In Group-II, the mean ± S.D before treatment was 
3.33 ± 2.15 and reduced to 2.66 ± 1.63 after 15 days, 1.4 ± 
1.35 after 30days and 1 ± 1.06 after 45 days of treatment. 
The test of significance shows that both Group-I and 
Group-II are highly significant with p- Value <0.001. 
In case of burning sensation in Vatarakta in Group-I, 
the mean ± S.D before treatment was 42.46 ± 7.08 and 
reduced to 38.4 ± 6.03 after 15 days, 2.2 ± 2.7 after 30days 
and 1.73 ± 2.78 after 45 days of treatment. 
 In Group-II, the mean ± S.D before treatment was 
42.2 ± 7.86 and reduced to 36.53 ± 10.9 after 15 days, 
30.66 ± 3.28 after 30days and 26.73 ± 3.26 after 45 days of 
treatment. The test of significance shows that both Group-I 
and Group-II are highly significant with p- Value <0.001. 
 In case of Uric acid in Vatarakta in Group-I, the 
mean ± S.D before treatment was 41.07 ± 18.70 and 
reduced to 36.86 ± 17.65 after 15 days, 32.13 ± 18.93 after 
30days and 29 ± 19.67 after 45 days of treatment. 
 In Group-II, the mean ± S.D before treatment was 
43.66 ± 15.54 and reduced to 37.33 ± 16.97 after 15 days, 
31.46 ± 18.06 after 30days and 27.4 ± 17.55 after 45 days 
of treatment. The test of significance shows that both 
Group-I and Group-II are highly significant with p- Value 
<0.001. 
In case of ESR in Vatarakta in Group-I, the mean ± 
S.D before treatment was 8.66 ± 0.52 and reduced to 8.57 ± 
0.53 after 15 days, 13.12 ± 17.95 after 30days and 13.14 ± 
19.61 after 45 days of treatment. 
 In Group-II, the mean ± S.D before treatment was 
14.02 ± 20.19 and reduced to 8.63 ± 0.58 after 15 days, 
8.46 ± 0.63 after 30days and 8.2 ± 0.71 after 45 days of 
treatment. The test of significance shows that both Group-I 
is significantly significant with p- Value <0.001, and group 
- II is insignificant at 5% level p- value> 0.05 . 
DISCUSSION 
 In the present study pain, swelling, burning 
sensation (Daha) were considered as sign and symptoms 
where as pruritus, discoloration of skin has been 
overlooked. 
 Regression in swelling of finger joints comparing 
the other joints were higher; the reason may be the upper 
limb joints are most mobile and free from having a 
tendency of dependant oedema. 
 Uric acid level was found decreased among both 
the groups significantly in Group-I (31.47%) and Group-II 
(37.25%) respectively. The reason may be both drugs 
Amrutadi Guggulu and Kaisora Guggulu caused the 
synthesis of Uric acid in course of metabolism and also 
excretion of Uric acid was better. 
 Decrease of burning sensation (Daha) was in both 
Group- I (22.91%) and in Group-II (39.02%) respectively. 
This may be due to predominance of Tikta rasa, Madhura 
Vipaka. ESR level of both the groups deceases in Group-I 
(5.69%) and Group-II (4.13%). The low response may be 
due to the drug poorly effective in sedimentation of RBC’s. 
 Acceptability of any drug rest on its fitness 
including safety. The effect of both Kaisora Guggulu and 
Amrutadi Guggulu on Vatarakta may be viewed that as 
treatment there is a recommendation of Virechana, 
Asthapana and Raktamokshyana furnished by veteran 
pioneers such as to win over Pitta and Vata dosha. Usually 
Virechana is advocated to excreta Pitta which can also be 
possible through excretion of Urine. These mala mutra 
together can be considered under Virechana as advocated 
against Vatarakta. As per the modern layout control of uric 
acid is possible through cessation of uric acid synthesis 
and excretion through urine. 
 The former effectiveness only possible through 
maintenance of proper metabolism as explained in 
Ayurveda. Defining the pharmacological effect and physic-
chemical analysis the drug Kaisora Guggulu and Amrutadi 
Guggulu are up to the requirement as desired. 
 An overall clinical implement and statistical 
assessment are also witnessed in favour of trial drugs in a 
significant manner. Correction in laboratory investigation 
is also another beneficent favour of drug appended. The 
question of acceptability of the trial drugs for the 
treatment of Vatarakta is no more remains apprehended 
rather it can be safely used for the purpose.  
CONCLUSION 
 From the observation of my study it is found that 
both the drugs are effective in reducing the sign and 
symptoms of Vatarakta but while coming to the 
comparison Amrutadi Guggulu is more effective than the 
Kaisora Guggulu in the present study.  
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